You are here: Industry Insights > PI3K

News List

Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or refractory marginal zone lymphoma, follicular lymphoma expresspharma
February 09, 2021
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, discovered by Rhizen Pharma and subsequently licensed to TG Therapeutics at an IND stage (TGR 1202) in 2012.
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer drugs
June 03, 2019
Novartis’ Piqray Approved as First PI3K Inhibitor for Breast Cancer.
FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer drugs
May 31, 2019
FDA Approves Piqray.
First PI3K inhibitor for breast cancer approved by FDA europeanpharmaceuticalreview
May 30, 2019
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
PI3K inhibitors show hope for rare bone cancers europeanpharmaceuticalreview
May 06, 2019
Scientists have used genome sequencing to gain a better understanding of the biology underlying chordoma…
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma drugs
April 18, 2019
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation worldpharmanews
August 24, 2018
Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS).
PI3K inhibitors carries hope for rare bone cancer patients europeanpharmaceuticalreview
October 13, 2017
Scientists have used whole genome sequencing to gain a better understanding of the biology underlying chordoma…